This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (7) Citing Articles via Google Scholar Google Scholar Articles by Erglis, A. Articles by Saltups, A. Search for Related Content PubMed Articles by Erglis, A. Articles by Saltups, A. Related Collections Related Article

A Randomized Comparison of Paclitaxel-Eluting Stents Versus Bare-Metal Stents for Treatment of Unprotected Left Main Coronary Artery Stenosis

Andrejs Erglis, MD, PhD, FESC, FACC^_*,_*, Inga Narbute, MD^_*, Indulis Kumsars, MD^_*, Sanda Jegere, MD^_*, Iveta Mintale, MD^_*, Ilja Zakke, MD, FESC^_*, Uldis Strazdins, MD^_* and Andris Saltups, MD, FACC, FRACP, MRACP

^_* Latvian Center of Cardiology, Pauls Stradins Clinical University Hospital, Riga, Latvia
Cabrini Medical Centre and Monash Medical Centre, Melbourne, Australia.

View larger version (15K): [in this window] [in a new window] [Download PPT slide]   Figure 1 Kaplan-Meier Curves: Freedom From Major Adverse Coronary Events At 6 months, the death, myocardial infarction, and target lesion revascularization (major adverse coronary events)-free survival rate was 70.0% in the bare-metal stent (BMS) group and 86.8% in the paclitaxel-eluting stent (PES) group (p = 0.036). PCI = percutaneous coronary intervention.